Snake venom phospholipase A2s exhibit strong virucidal activity against SARS-CoV-2 and inhibit the viral spike glycoprotein interaction with ACE2

Andrei E. Siniavin(Institute of Bioorganic Chemistry), Maria A. Streltsova(Institute of Bioorganic Chemistry), Maria A. Nikiforova(Ministry of Health of the Russian Federation), Denis S. Kudryavtsev(Institute of Bioorganic Chemistry), Svetlana D. Grinkina(Ministry of Health of the Russian Federation), Vladimir А. Gushchin(Ministry of Health of the Russian Federation), Vera A. Mozhaeva(Institute of Bioorganic Chemistry), Vladislav G. Starkov(Institute of Bioorganic Chemistry), Alexey V. Osipov(Institute of Bioorganic Chemistry), Sarah C. R. Lummis(University of Cambridge), Victor I. Tsetlin(Institute of Bioorganic Chemistry), Yuri N. Utkin(Institute of Bioorganic Chemistry)
Cellular and Molecular Life Sciences
October 29, 2021
10.1007/s00018-021-03985-6
Cited by 43Open Access
Full Text

Abstract

Related Papers

Phospholipase A<sub>2</sub>Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
Edward A. Dennis, Jian Cao, Yuan‐Hao Hsu et al.|Chemical Reviews|2011|1.2k
Phospholipases A2: Unveiling the secrets of a functionally versatile group of snake venom toxins
José Marı́a Gutiérrez, Bruno Lomonte|Toxicon|2012|261
A sensitive and continuous fluorometric assay for phospholipase A2 using pyrene-labeled phospholipids in the presence of serum albumin
François Radvanyi, Lynda Jordan, Françoise Russo‐Marie et al.|Analytical Biochemistry|1989|244
Antitumoral Activity of Snake Venom Proteins: New Trends in Cancer Therapy
Leonardo A. Calderón, Juliana C. Sobrinho, Kayena Delaix Zaqueo et al.|BioMed Research International|2014|223
From snake venom toxins to therapeutics – Cardiovascular examples
Cho Yeow Koh, R. Manjunatha Kini|Toxicon|2011|220